An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
Status:
Completed
Trial end date:
2013-05-02
Target enrollment:
Participant gender:
Summary
This is an open-label extension study to assess the long-term safety and tolerability of
pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).